List view / Grid view
Strong evidence of long-term efficacy of the IL-13 inhibitor lebrikizumab…
Strong evidence of long-term efficacy of the IL-13 inhibitor lebrikizumab for atopic dermatitis has been demonstrated in Eli Lilly’s two-year extension trial.
The results of Eli Lilly and Company’s double-blind, placebo-controlled Phase…
The results of Eli Lilly and Company’s double-blind, placebo-controlled Phase III trials for Olumiant® are encouraging for patients suffering with alopecia.
Lebrikizumab achieved at least 75 percent skin clearance in more…
Lebrikizumab achieved at least 75 percent skin clearance in more than half of patients with atopic dermatitis (AD), shows Phase III study.
